Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection.

Poncelet, Arthur; Verschelden, Gil; Colard, Martin; Hildebrand, Marc; Hites, Maya; Yin, Nicolas; Michel, Charlotte; Grimaldi, David; De Wilde, Virginie

Poncelet, Arthur; Verschelden, Gil; Colard, Martin; Hildebrand, Marc; Hites, Maya; Yin, Nicolas; Michel, Charlotte; Grimaldi, David; De Wilde, Virginie.

Affiliation

Poncelet A; Departement of Hematology, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Verschelden G; Clinic of Infectious Disease, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Colard M; Departement of Hematology, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Hildebrand M; Department of Internal Medicine, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Hites M; Clinic of Infectious Disease, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Yin N; Department of Microbiology, Laboratoire hospitalier universitaire de Bruxelles (LHUB-ULB)- Université libre de Bruxelles, Brussels, Belgium.
Michel C; Department of Microbiology, Laboratoire hospitalier universitaire de Bruxelles (LHUB-ULB)- Université libre de Bruxelles, Brussels, Belgium.
Grimaldi D; Departement of Intensive Care, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
De Wilde V; Departement of Hematology, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Leuk Lymphoma ; 63(1): 253-255, 2022 01.

Article in En | MEDLINE | ID: mdl-34521312

Subject(s)

COVID-19; Antibodies, Viral; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: En Journal: Leuk Lymphoma Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2022 Type: Article Affiliation country: Belgium

Fulltext

XML

PubMed Links

Search on Google